- MILITARY-INDUSTRIAL COMPLEX: Defense Dept. Contracts for Dec. 19, 2014
- "Hobbit" will Dominate Boxoffice; "Wild" & "Big Eyes" Slated for Debut
- MILITARY-INDUSTRIAL COMPLEX: Defense Dept. Contracts for Dec. 18, 2014
- Buckeye Elite National Basketball Showcase To Take Place in Huntington This Weekend
- CARIBBEAN VIEW: Venezuela in financial difficulty, will Petro Caribe survive?
- OP-ED: Commemorate Universal Children’s Day: End Child Labor
- OP-ED: Do Wars Really Defend America’s Freedom?
- Fans can wish Herd good luck with recorded video message
- Senator Rockefeller to Deliver Farewell Address Thursday on Floor of United States Senate
- Secretary Tennant Urges West Virginians To Shop Small on Saturday, November 29
Biomedical sciences researcher to present results of clinical trials on personalized chemotherapy
Thursday, June 12, 2014 - 03:21 Updated 26 weeks ago Special to HNN Provided by Marshall University
He will be discussing the results of clinical trials conducted at the Edwards Comprehensive Cancer Center. The studies tested ChemoID, a cell culture method he developed with colleague Dr. Jagan Valluri to measure the sensitivity of patients' tumors to chemotherapy treatment for lung, brain/spine and breast cancer.
He says more evaluation of the technology is needed, but preliminary tests on a small number of patients found ChemoID 100 percent accurate in predicting which drug is more effective in treating patients affected by brain cancer if the tumor-initiating cancer stem cells were evaluated.
"Oncologists every day face many challenges in determining the best course of therapy for an individual cancer patient," says Claudio. "The basic problem is that patients with similar diagnoses don't always respond to the same chemotherapy. This technology we have developed could help physicians select the appropriate chemotherapy for an individual patient giving them an edge in the fight against cancer."
He says the good news for cancer patients is that ChemoID may make possible personalized treatment by predicting the most effective drug combination to successfully target that specific patient's cancer increasing the chance the drugs will work and perhaps reducing side effects by helping the patient avoid unnecessary drugs.
In addition to presenting his own research at the conference, Claudio will be moderating a session, "Advances in Oncology and Anticancer Research. Cancer Pathology."
Summaries of the research presented at the meeting will be published in the journal Frontiers in Bioscience.